LF
BMRN icon

Lee Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lee Financial’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30
Closed -$2.89K – 237
2023
Q4 		$2.89K Hold
30
– – ﹤0.01% 667
2023
Q3 		$2.65K Hold
30
– – ﹤0.01% 628
2023
Q2 		$2.6K Hold
30
– – ﹤0.01% 605
2023
Q1 		$2.92K Hold
30
– – ﹤0.01% 600
2022
Q4 		$3.1K Hold
30
– – ﹤0.01% 615
2022
Q3 		$3K Sell
30
-2
-6% -$178 ﹤0.01% 606
2022
Q2 		$2K Buy
32
+2
+7% +$159 ﹤0.01% 668
2022
Q1 		$2K Buy
+30
New +$2.51K ﹤0.01% 620
2018
Q3 		– Sell
-38
Closed -$4K – 499
2018
Q2 		$4K Hold
38
– – ﹤0.01% 636
2018
Q1 		$3K Buy
+38
New +$3.26K ﹤0.01% 662

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Lee Financial's BMRN Position: Q1 2024 in Review

Lee Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 30 shares — an estimated $2.89K sold.

Lee Financial first reported a position in BMRN in Q1 2018 and held it in 10 quarters. The position peaked at $4K in Q2 2018. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Lee Financial reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Lee Financial sold 30 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $2.89K.
  • Lee Financial first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 10 quarters.
  • Lee Financial's BioMarin Pharmaceuticals position peaked at $4K in Q2 2018.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Lee Financial's 13F filing for Q1 2024, filed 15 May 2024.